P1022 RANDOMIEZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS SPARING REGIMEN

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The optimal strategy is not known for women who initiate combination antiretroviral therapy during pregnancy. HIV-infected women who begin antiretroviral therapy during pregnancy are currently being treated with a variety of initial antiretroviral regimens. Data from ACTG 367 indicate that by the third trimester, 38% of HIV-invected pregnant women who initiate antiretroviral therapy during pregnancy are taking a protease inhibitor based regimen with nelfinavir as the most commen agent used and 15% are on a protease inhibitor-sparing regimen with 3 drugs. The proportion of women who received nevirapine-based regiments has increased over time, reaching 28% among deliveries from 7/00 to 2/01.